Targeted News Service

ESCMID: Sanofi's Nuvaxovid COVID-19 Vaccine Showed Better Tolerability Than MNEXSPIKE in Head-to-head Study
April 18, 2026

PARIS, France, April 18 (TNSxrep) -- Sanofi, a life sciences company, issued the following news release:

* * *

Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

* First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tol . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form